Abstract
Introduction

CD4
+ and CD8 + αβTCR-expressing T cells are central players in adaptive immunity. The αβTCR on CD4 + T cells recognizes complexes of peptide and MHC class II molecules (pMHCII), whereas the αβTCR on CD8 + T cells recognizes complexes of peptide and MHC class I molecules (pMHCI). TCR diversity is generated by somatic gene recombination of variable (V), diversity (D; for TCRβ only) and joining (J) gene segments as well as by junctional diversity within the complementarity-determining region (CDR)3 loops created by 'random' joining, and nucleotide deletion and insertion at the V(D)J junctions. In the human TCR loci, there are 48 Vβ, 2 Dβ, 13 Jβ, 45 Vα and 50 Jα functional gene segments (1) , giving rise to a potentially enormous diversity in the TCR repertoire. TCR diversity is considered to be favourable for effective immune control, particularly with persistent viruses (2) . One relevant mechanism is that TCR diversity bolsters against viral escape mutants that affect TCR recognition (3). Notwithstanding this notion, there are many examples of biased TCR usage of virus-specific cytotoxic CD8 + T cells that recognize particular pMHCI complexes (2) . Some of the examples of biased TCR usage relate to private TCR repertoires that are not shared between individuals responding to the same pMHC complex, whereas other examples of biased TCR usage are public where T cells of different individuals use the same TCR sequence (2) . As a possible structural mechanism for TCR bias in CD8 + T cells, it was suggested that the TCR repertoire more easily would become restricted and biased if the pMHCI complex is structurally featureless or bulged compared with most pMHCI complexes that are featured (2) . For CD4 + T cells less is known about TCR bias; but also for such cells, there are examples on biased TCR usage for recognition of given pMHCII complexes (4-11). Of note, gluten-reactive T cells of coeliac disease patients represent some of these examples (10, 11) .
Coeliac disease is a human chronic inflammatory disease of the intestine driven by CD4 + T-cell responses toward the causative antigen, ingested dietary cereal gluten proteins (12, 13) . Coeliac disease has a particular strong association to the HLA class II molecule HLA-DQ2.5, which is expressed by about 90% of the patients. The remaining patients express either HLA-DQ8 or DQ2.2; the latter contains a DQα chain different from that of DQ2.5. Previous studies have demonstrated that intestinal CD4 + T cells in coeliac disease patients recognize a variety of similar gluten-derived peptides when presented by HLA-DQ2.5, HLA-DQ2.2 or HLA-DQ8 molecules (reviewed in ref. 14) . Although T-cell responses to many gluten epitopes exist in coeliac disease patients, responses to a few gluten epitopes dominate. In HLA-DQ2.5 + coeliac disease patients, two epitopes derived from the α-gliadin fraction of wheat gluten, the DQ2.5-glia-α1 and DQ2.5-glia-α2 epitopes, are immunodominant along with a few other epitopes (15, 16) , whereas in HLA-DQ8 coeliac disease patients, T-cell reactivity to the DQ8-glia-α1 epitope seems to dominate the response (17) .
Interestingly, it was recently reported that DQ8-glia-α1-specific T cells of coeliac disease patients have a biased usage of the human TCRβ variable (TRBV) 9 gene segment, coupled with a preferred pairing and biased usage of the human TCRα variable (TRAV) 26-2 gene segment (10) . Similarly, we reported a biased usage of the TRBV7-2 gene segment in T cells of coeliac disease patients specific for the DQ2.5-glia-α2 epitope (11) . Most of these TCRs express a non-germline-encoded Arg residue in position 5 of the CDR3β loop, and the amino acid sequence ASSxRxTDTQY can be found in two-thirds of the CDR3β loops of these cells. In this work, we perform paired analysis of the Vα chain usage in these cells and report a seemingly invariant usage of the TRAV26-1 gene segment by the DQ2.5-glia-α2-specific T cells that express the canonical ASSxRxTDTQY CDR3β loop.
Methods
T cells
The T-cell clones cultured from intestinal biopsies of coeliac disease patients have been reported previously (11) . Patient CD823 was on a gluten-free diet when given a 3-day gluten challenge before a blood sample was taken 6 days later as described in Qiao et al. (11) . Of 51 DQ2.5-glia-α2-tetramersorted T cells of this coeliac disease patient, we found 19 unique TRBV nucleotide sequences. In this study, we used frozen cDNA to amplify the TRAV genes from 18 of 19 T cells carrying unique TRBV sequences.
CD1030 was a coeliac disease patient on a gluten-containing diet (untreated), whereas patients CD525 and CD801 had been treated with a gluten-free diet when they donated blood for this study. From peripheral blood, tetramer-binding CD4 + T cells were bead-enriched and FACS sorted with a protocol modified from Moon et al. (18) . Cells sorted from peripheral blood of coeliac disease patients were then expanded in vitro and cloned by limited dilution. RNA was isolated from 2-4 million cells of each T-cell clone using the MiniRNA Kit (Qiagen, Hilden, Germany).
All patients included in this study have given informed written consent. This study was approved by the regional ethics committee.
TCR sequencing
Three different approaches, tailing and cloning, multiplex forward primer PCR from single-cell cDNA and SMART template-switch PCR, were used to identify and sequence the TRAV gene segments.
Tailing and cloning
cDNA tailing, semi-nested PCR and cloning of TCR genes of T-cell clones derived from intestinal biopsy tissue were reported previously (11) .
Multiplex forward primer PCR from single-cell cDNA
The TRAV gene was amplified from frozen cDNA made from FACS single-cell sorted DQ2.5-glia-α2-tetramer-binding and TRBV7-2-expressing T cells from peripheral blood of glutenchallenged patient CD823. Two rounds of semi-nested PCR using multiple forward primers designed for each of the 45 functional TRAV genes combined with reverse primers annealing with the TRAC gene was performed (Table 1 and Fig. 1 ). In detail, 2 µl of cDNA synthesized with gene-specific primers (TRAC-and TRBC-specific primers) was used as template in each of the three first PCRs. In this first PCR, 500 nM of each of the 9 or 10 forward primers each annealing one or two TRAV gene segments as shown in Table 1 , 500 nM TRAC_rev primer and 200 μM dNTP, in a total final volume of 15 μl. In the second PCR for visualization, 1 μl of the first PCR product was amplified with the same mixture of forward primers and 500 nM of TRAC_MluI_rev primer in a total final volume of 20 μl. All PCRs were performed with the Phusion DNA polymerase (Thermo Scientific, Waltham, MA, USA), for 8 cycles (98°C for 20 s, 60°C for 40 s and 72°C for 40 s) followed by 32 (first PCR) or 22 (second PCR) cycles of (98°C for 20 s, 55°C for 40 s and 72°C for 40 s) and a final elongation at 72°C for 3 min. About 8 μl of the second PCR product was loaded onto a 1% agarose gel and wells with expected bands at 310-510 bp were identified for further PCR amplification. About 1 µl of the first PCR product from those wells was amplified in each of the three second PCR reactions using a mixture of three forward TRAV primers and the TRAC_ MluI_rev primer in a total final volume of 15 µl. About 8 μl of the PCR product was loaded onto a 1% agarose gel and wells with expected bands at 140-340 bp were identified for a final PCR amplification and subsequent sequencing. In the last set of PCR reactions, 1 µl of the first PCR was amplified in each of the three final PCR reactions using a single forward TRAV primers and the TRAC_MluI_rev primer in a total final volume of 20 µl. About 8 μl of the PCR product was loaded onto a 1% agarose gel and wells with expected bands at 140-340 bp were identified for subsequent sequencing. We did not find clones expressing more than one Vα chain.
Template-switch PCR
About 40-100 ng of total RNA from T-cell clones established from tetramer-sorted T cells were used in cDNA synthesis together with a template-switch oligo, based on previously published SMART protocol (19) . In short, 1.2 µM of RT oligo [(AAGCAGTGGTATCAACGCAGAGTAC)-r(GGG)] was included in the reverse transcription reaction, together with 2 mM of dithiothreitol, 1 mM of dNTP, 1.2 µM of oligo_dT (CTGAATTCTTTTTTTTTTTTTTTT), RNAsin and 10 U µl -1 SuperScript II (Invitrogen) in a total reaction volume of 10 µl. The RT oligo acts as the template-switch oligo during the reverse transcription reaction and introduces a universal tag sequence that can be amplified in a subsequent PCR reaction. The PCR was done with 0.5 µl TRAV3, TRAV16  I  I-3  AV9  tggtatgtccaatatcctggag  TRAV9-1/-2  I  I-3  AV12  tgttccagagggagcca  TRAV12-1/-2/-3  I  I-3  AV21  caggaggtgacgcagattcc  TRAV21  I  I-21  AV24  cagcttcccttccagcaat  TRAV24  I  I-21  AV29  aattcaccatccctgagcgt  TRAV29  I  I-21  AV30  tcaagccgtgatcctccg  TRAV30  I  I-30  AV34  ctcagtccttgatcgtccaag  TRAV34  I  I-30  AV39  tctgttcctgagcatgcagg  TRAV39  I  I-30  AV40  gtcaagcagacgggccaa  TRAV40  I  I- TRAV6, TRAV17  III  III-4  AV18  cggttacccagacagaaggc  TRAV18  III  III-18  AV19  cagaaggtaactcaagcgcag  TRAV19  III  III-18  AV20  aagaccaggtgacgcagagt  TRAV20  III  III-18  AV22  acaagtggagcagagtcctcc  TRAV22  III  III-22  AV27/35  tggggaaggtcctgtcct  TRAV27, TRAV35  III  III-22  AV36  cctctatctctggttgtccacg  TRAV36  III  III-22  TRAC_rev  agtcagatttgttgctccaggcc  TRAC_MluI_rev atacgcgttctctcagctggtacacgg Fig. 1 . Flowchart of TRAV gene sequencing by multiplex PCR. About 10 µl of cDNA was synthesized from lysate of one single FACS-sorted T cell with reverse primers specific for human TRAC and TRBC genes. After cDNA synthesis, 5 µl of water was added and 2 µl of diluted cDNA was used as template in the first round of PCR. Three separate first PCR reactions were performed each using a mixture of 9-10 forward TRAV primers, combined with the TRAC_rev primer. About 1 µl of the first PCR product was then used as template in up to three more rounds of PCR reactions, all using the TRAC_MulI_rev reverse primer. The first round used the same 9-10 forward primer mix, the second used three forward primer mix based on productive bands in the previous PCR and finally, the last round of PCR was performed with single TRAV forward primer for sequencing purposes. The flowchart illustrates the pathway for identifying a putative TRAV29 gene segment and productive PCR reactions are shaded.
72°C for 40 s), followed by 22 cycles (98°C for 10 s, 68°C for 30 s and 72°C for 40 s) and a final elongation at 72°C for 4 min. PCR products were subjected to subsequent sequencing on an ABI3730 machine. All sequences were analysed with the IMGT/V-QUEST online resource (20) . Mixed traces or sequences returned with no V-QUEST results were classified as failed sequencing.
Results
Specific T cells expressing TRBV7-2 genes with the canonical CDR3β use the TRAV26-1 gene segment
Previously, systematic TCR sequencing of in vitro generated DQ2.5-glia-α2-specific T-cell clones derived from intestinal tissues of coeliac disease patients has revealed an overusage of the TRBV7-2 gene segment (11) . Closer inspection of the data revealed that five of six T-cell clones with this TRBV usage expressed the canonical amino acid sequence ASSxRxTDTQY in CDR3β and used the TRAV26-1 gene segment. To expand the data set, we attempted to sequence the TRAV genes of a panel of DQ2.5-glia-α2-specific T cells from cDNA of single cells sorted from one coeliac disease patient, CD823. The TRBV7-2 gene sequences of these cells were previously published in Qiao et al. (11) . We performed seminested PCR using multiplex degenerate forward primers designed to cover 45 functional TRAV genes, combined with reverse primers annealing to the TRAC gene. We succeeded in sequencing TRAV genes of 15 out of 18 DQ2.5-glia-α2-specific T-cell clones. Nine of these T-cell clones shared the canonical ASSxRxTDTQY CDR3β sequence. All these nine clones used the TRAV26-1 gene segment. In a different approach, we used in vitro cultured T-cell clones from FACS-sorted DQ2.5-glia-α2-tetramer-binding T cells from peripheral blood of HLA-DQ2.5-expressing coeliac disease patients. Phenotypically, these cells were effector memory T cells that were CD3
− in blood. The specificity of these clones was confirmed by re-staining with tetramer and by specific proliferation response to the DQ2.5-glia-α2 epitope peptide (A. Christophersen et al., in preparation). From 68 effector memory DQ2.5-glia-α2-specific T-cell clones from three coeliac disease patients, we successfully sequenced both the TRAV and TRBV genes of 46 (Table 2) . We observed a certain degree of clonal expansion, giving a total of 32 unique clones. Twenty-two of these clones used the TRBV7-2 gene segment, confirming the previous finding of over-usage of this gene segment among DQ2.5-glia-α2-specific T cells from coeliac disease patients. Sixteen of these 22 TRBV7-2 genes had the canonical ASSxRxTDTQY CDR3β sequence, and all these 16 unique clones used TRAV26-1 (Table 3) . Of the remaining 22 T-cell clones that we failed to obtain paired TCRα and TCRβ sequences from, we had partial sequences from eight T-cell clones (four with TCRα but no TCRβ, and four with TCRβ but no TCRα). TRAV26-1 was found in two T-cell clones with no TCRβ sequences and TRBV7-2 was found in two T-cell clones with no TCRα sequences. To summarize, we have sequenced the TRAV genes of 30 unique DQ2.5-glia-α2-specific T cell clones that use TRBV7-2 Of 68 T cells analysed in total, both the TRAV and TRBV genes were successfully sequenced in 46, representing 32 unique clones. Row 1 shows that in total, 28 out of 42 unique DQ2.5-glia-α2 T-cell clones analysed use the TRBV7-2 gene. Rows 1.1 and 1.2 show the prevalence of conserved Arg residue in position 5 of the CDR3β loop and the prevalence of the canonical ASSxRxTDTQY CDR3β loop, respectively. Rows 3.1 and 3.2 show the prevalence of TRAV26-1 in DQ2.5-glia-α2 T-cell clones that do not use or use the TRBV7-2 gene segment, respectively. The sums of the numbers in rows 3.1 and 3.2 can be found in row 3, which shows the prevalence of TRAV26-1 in all DQ2.5-glia-α2 T-cell clones analysed, irrespective of TRBV usage. Similarly, the numbers in row 3.2 are further split into prevalence of TRAV26-1 in canonical and non-canonical TRBV7-2 chain, in rows 3.2.1 and 3.2.2, respectively. TCC, T-cell clone; scPCR, single-cell PCR.
a Only cells using the TRBV7-2 chain were sorted and subjected to TRBV sequencing; of these, only DQ2.5-glia-α2-reactive cells were subjected to further TRAV sequencing.
b
Eighteen of the 19 T-cell clones were subjected to TRAV sequencing and informative sequences were found in 15 clones that were subjected to further analysis. with the canonical ASSxRxTDTQY CDR3β sequence from a total of eight coeliac disease patients. We found that the TRAV26-1 gene segment was uniformly used by all these clones with no exception. The observed pairing of TRAV26-1 with TRBV7-2 genes in DQ2.5-glia-α2-specific T cells seems to occur only in TCRs that have the canonical ASSxRxTDTQY CDR3β sequence. Of the 13 TRBV7-2-expressing DQ2.5-glia-α2-specific T-cell clones that had non-canonical CDR3β loops, we found two cases of TRAV26-1 usage (Table 3) . Among the remaining 4 intestine-derived and 10 blood-derived non-TRBV7-2-expressing DQ2.5-glia-α2-specific T-cell clones, we observed three cases of TRAV26-1 usage (Table 3) .
TCR pairing in coeliac disease 17
There are no shared motifs in the TRAV26-1 CDR3α loops DQ2.5-glia-α2-specific TCRs that use TRBV7-2 and that have the canonical ASSxRxTDTQY CDR3β sequence, all use the TRBJ2-3 gene segment. In contrast, the same cells that all use TRAV26-1 genes utilize a variety of different TRAJ gene segments. We did not observe any recurrent motifs in the CDR3α loops of these cells (Table 4) .
Discussion
We have previously reported over-usage of the TRBV7-2 gene segment of TCRs specific to the DQ2.5-glia-α2 epitope (11) . Using different sequencing approaches, we have found that in these T cells, the TRAV26-1 gene segment was uniformly associated with TRBV7-2 that has the canonical ASSxRxTDTQY CDR3β sequence. The fact that this was observed in a total of 30 unique T-cell clones derived from both the intestinal tissue and peripheral blood of coeliac disease patients, makes this one of the largest studies on TCRα and TCRβ chain pairing in antigen-specific TCRs and a clear example of a biased TCR usage with a public repertoire of CD4 + T cells that recognize a given pMHCII complex. A few dozen solved TCR-pMHC trimolecular structures have given insights in the general mechanism of TCR interactions with pMHC (21) . However, detailed knowledge of exactly what makes a particular TCR a good or poor binder of a particular pMHC complex is lacking. A non-germlineencoded Arg residue was often found in position 5 of the CDR3β loops of TRBV7-2 encoded TCRs specific to DQ2.5-glia-α2. We have speculated whether this positively charged residue could make charge-charge interaction with the negatively charged Glu residue in the DQ2.5-glia-α2 peptide. The fact that about two-thirds of DQ2.5-glia-α2-specific TRBV7-2 sequences used the same TRBJ gene segment (TRBJ2-3), and that the CDR3β loops of these cells were highly similar, argues for additional interactions with the pMHC complex contributed by the rest of the CDR3β loop. The seemingly strict pairing of these TCRβ chains with one particular TRAV gene segment, the TRAV26-1, is interesting. Among DQ8-glia-α1-specific TCRs, it was recently reported by Broughton et al. (10) that the TRBV9 gene segment was preferentially used. In addition, the authors reported a preferential pairing with TRAV26-2 that was suggested to contribute to the observed TRBV bias.
Because of a lack of crystal structure data, we are cautious to make specific claims about the structural explanation to our findings. We did not observe over-usage of TRAV26-1, or any other particular TRAV gene segments, in DQ2.5-glia-α2-specific TCRs that use TRBV7-2 but do not have the canonical CDR3β loop. This argues against a general pairing preference between these two chains. We observed variable usage of TRAJ genes and no apparent recurring motifs in the CDR3α sequences of the paired TRAV26-1 genes. This indicates that the CDR3α loops may not make direct contact with the pMHC complex and the preference for TRAV26-1 may be contributed by the germline-encoded residues, in combination with the canonical TCRβ. How the structural mechanisms potentially underlying the TCR bias of pMHCI recognition (featureless or bulged pMHCI) (2) relate to biased TCR recognition of pMHCII is unclear. However, it appears likely that for CD4 + T-cell recognition of gluten epitopes in coeliac disease, with the several examples of biased usage and preferred pairing of TCR α-and β-chains, there is likely some strong underlying the TCR biology resulting in this phenomenon.
Until recently, the technical difficulties of paired TCRα and TCRβ analyses have precluded large-scale study on the pairing preference of TRAV and TRBV genes in single T cells. In this study, we have used several unbiased approaches to TCR sequencing. Combined with sorting of tetramer-binding cells, we have collected paired TCR sequence data of a relatively large number of T cells specific to the same gluten epitope that is important in the pathogenesis of coeliac disease. The TCR repertoire of these cells is the result of in vivo antigen selection, and comparison of TCR sequences of cells with the same antigen specificity provides important additional information to in vitro mutagenesis and binding analyses. Ultimately, crystal structure studies will provide detailed structural basis for TCR repertoire bias. Further, high-throughput sequencing of TCRs specific for both the immunodominant and other gluten epitopes should help to understand the relevance of TCR repertoire bias for the development of coeliac disease.
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